problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201258458-62problendo-4680Research ArticleСтатьиArticlesДвухфазный инсулиновый аналог НовоМикс 30: решение ключевых проблем инсулинотерапии двухфазными человеческими инсулинами у пациентов с сахарным диабетом 2-го типаBiphasic insulin analog NovoMix 30 is a possible solution to overcome key problems of biphasic human insulin therapy for DM type 2 patientsSurkovaE Velenasurkova@mail.ru201215082012584ТОМ 58, №4 (2012)5862Copyright © Surkova E.V., 20122012Surkova E.V.Surkova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4680

В обзоре анализируются публикации, посвященные использованию двухфазного аналога инсулина аспарт 30/70 (НовоМикс 30) в терапии пациентов с сахарным диабетом 2-го типа. Рассматриваются клинические и фармакоэкономические преимущества НовоМикс 30 перед двухфазными человеческими инсулинами. Освещаются вопросы клинической инертности врачей и психологической инсулинорезистентности пациентов, а также возможности решения ключевых проблем инсулинотерапии больных сахарным диабетом 2-го типа с помощью двухфазного аналога инсулина аспарт 30/70.

This review discusses publications on the usage of biphasic analogue insulin aspart 30/70 (NovoMix 30) in the treatment of patients with type 2 diabetes mellitus. Data on the clinical and pharmaco-economic advantages of NovoMix 30 versus biphasic human insulin was analyzed. The problems of doctor's clinical inertia and patient's psychological insulin resistance, as well as possible solutions to key problems of insulin therapy with help of biphasic insulin aspart 30/70 were discussed.

сахарный диабетдвухфазный аналоговый инсулинтерапия инсулиномdiabetes mellitusbiphasic insulin analogsinsulin therapyReferencesАлгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, 5-й вып. М 2011.Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, 5-й вып. М 2011.Сунцов Ю.И., Болотская Л.Л., Маслова О.В., Казаков И.В. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации. Сахарный диабет 2011; 1: 15-18.Сунцов Ю.И., Болотская Л.Л., Маслова О.В., Казаков И.В. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации. Сахарный диабет 2011; 1: 15-18.Shah D.R., Hux J.E., Laupacis A., Zinman B., Walraven C. Clinical Inertia in Response to Inadequate Glycemic Control. Do specialists differ from primary care physicians? Diabet Care 2005; 28: 3: 600-606.Shah D.R., Hux J.E., Laupacis A., Zinman B., Walraven C. Clinical Inertia in Response to Inadequate Glycemic Control. Do specialists differ from primary care physicians? Diabet Care 2005; 28: 3: 600-606.O'Connor P. Commentary - improving diabetes care by combating clinical inertia. Health Serv Res 2005; 40: 6: 1854-1860.O'Connor P. Commentary - improving diabetes care by combating clinical inertia. Health Serv Res 2005; 40: 6: 1854-1860.Polonsky W.H., Fisher L., Guzman S., Villa-Caballero L., Edelman S.V. Psychological insulin resistance in patients with type 2 diabetes. Diabet Care 2005; 28: 10: 2543-2545.Polonsky W.H., Fisher L., Guzman S., Villa-Caballero L., Edelman S.V. Psychological insulin resistance in patients with type 2 diabetes. Diabet Care 2005; 28: 10: 2543-2545.Karter A.J., Subramanian U., Saha Ch., Crosson J.G., Parker M.M., Swain B.E., Moffet H.H., Marrero D.G. Barriers to insulin initiation. Diabet Care 2010; 33: 4: 733-735.Karter A.J., Subramanian U., Saha Ch., Crosson J.G., Parker M.M., Swain B.E., Moffet H.H., Marrero D.G. Barriers to insulin initiation. Diabet Care 2010; 33: 4: 733-735.Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995; 12: 449-450.Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995; 12: 449-450.Overmann H., Heinemann L. Injection-meal interval: recommendations of diabetologistsand how patients handle it. Diabet Res Clin Pract 1999; 43: 137-142.Overmann H., Heinemann L. Injection-meal interval: recommendations of diabetologistsand how patients handle it. Diabet Res Clin Pract 1999; 43: 137-142.McSorley K.M., Bell P.M., Jacobsen L.V., Kristensen A., Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double blind cross-over study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530-539.McSorley K.M., Bell P.M., Jacobsen L.V., Kristensen A., Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double blind cross-over study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530-539.McNally P.G., Dean J.D., Morris .D., Wilkinson P.D., Compion G., Heller S.R. Used continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabet Care 2007; 30: 1044-1048.McNally P.G., Dean J.D., Morris .D., Wilkinson P.D., Compion G., Heller S.R. Used continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabet Care 2007; 30: 1044-1048.Rizvi A.A., Lightelm R.J. The use of premixed insulin analogs in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin 2007; 2: 68-79.Rizvi A.A., Lightelm R.J. The use of premixed insulin analogs in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin 2007; 2: 68-79.Boehm B.O., Home P.D., Kamp B.N.M., Behrend C., Kamp N.M., Lindhoolm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.Boehm B.O., Home P.D., Kamp B.N.M., Behrend C., Kamp N.M., Lindhoolm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.Boehm B.O., Vaz J.A., Bronsted L., Home P.D. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Inter Med 2004; 15: 496-502.Boehm B.O., Vaz J.A., Bronsted L., Home P.D. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Inter Med 2004; 15: 496-502.Heise T., Heinemann L., Hovelmann U., Brauns B., Nosek L., Haahr H.L., Olsen K.J. Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy. Diabet Care 2009, 32: 1431-1433.Heise T., Heinemann L., Hovelmann U., Brauns B., Nosek L., Haahr H.L., Olsen K.J. Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy. Diabet Care 2009, 32: 1431-1433.Shestakova M., Sharma S.K., Almustafa M., Min K.W., Ayad N., Azar S.T., Dansiulesku R., Khutsoan D., Guler S. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin 2007; 23: 12: 3209-3214.Shestakova M., Sharma S.K., Almustafa M., Min K.W., Ayad N., Azar S.T., Dansiulesku R., Khutsoan D., Guler S. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin 2007; 23: 12: 3209-3214.Gao Y., Guo X. Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin <7%: the results from the PRESENT study. Chinese Med J 2010; 123: 9: 1107-1111.Gao Y., Guo X. Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin <7%: the results from the PRESENT study. Chinese Med J 2010; 123: 9: 1107-1111.Davidson J.A., Liebl A., Christiansen J.S., Flucher G., Lightelm R.J., Brown D., Gylvin T., Kawamori N. Risk for nocturnal hypoglycemia with biphasic insulin Aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a metaanalysis. Clin Ther 2009; 31: 8: 1641-1651.Davidson J.A., Liebl A., Christiansen J.S., Flucher G., Lightelm R.J., Brown D., Gylvin T., Kawamori N. Risk for nocturnal hypoglycemia with biphasic insulin Aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a metaanalysis. Clin Ther 2009; 31: 8: 1641-1651.Morgan C.L., Evans M., Toft A.D., Jankin-Jones S., Pool C.D., Currie C.J. Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study. Clin Ther 2011; 33: 27-35.Morgan C.L., Evans M., Toft A.D., Jankin-Jones S., Pool C.D., Currie C.J. Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study. Clin Ther 2011; 33: 27-35.Velojic-Golubovic M., Mikic D., Pesic M., Dimic D., Radencovic S., Antic S. Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Inv 2009; 32: 23-27.Velojic-Golubovic M., Mikic D., Pesic M., Dimic D., Radencovic S., Antic S. Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Inv 2009; 32: 23-27.Ohira M., Endo K., Oyama T., Yamaguchi T., Ban N., Kawana H., Nagayama D., Nagumo A., Saiki A., Murano T., Watanabe H., Miyashita Y., Shirai K. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabol Clin Experiment 2011; 60: 78-85.Ohira M., Endo K., Oyama T., Yamaguchi T., Ban N., Kawana H., Nagayama D., Nagumo A., Saiki A., Murano T., Watanabe H., Miyashita Y., Shirai K. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabol Clin Experiment 2011; 60: 78-85.Fakhoury W.K.H., Richter H., Christensen T.E. Real-Life Dosage and Clinical Efficacy of Biphasic Insulin Preparations in Patients With Type 2 Diabetes. Adv Ther 2010; 27: 11: 859-869.Fakhoury W.K.H., Richter H., Christensen T.E. Real-Life Dosage and Clinical Efficacy of Biphasic Insulin Preparations in Patients With Type 2 Diabetes. Adv Ther 2010; 27: 11: 859-869.Valentine W.J., Pollock R.F., Plun-Favreau J., White J. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Curr Med Res Opin 2010; 26: 6: 1399-1412.Valentine W.J., Pollock R.F., Plun-Favreau J., White J. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Curr Med Res Opin 2010; 26: 6: 1399-1412.Palmer J.L., Gibbs M., Scheijbeler WKFH, Kotchie R.W., Nielsen S., White J., Valentine W.J. Cost-Effectiveness of Switching to Biphasic Insulin Aspart in Poorly-Controlled Type 2 Diabetes Patients in China. Adv Ther 2008; 25: 8: 752-774.Palmer J.L., Gibbs M., Scheijbeler WKFH, Kotchie R.W., Nielsen S., White J., Valentine W.J. Cost-Effectiveness of Switching to Biphasic Insulin Aspart in Poorly-Controlled Type 2 Diabetes Patients in China. Adv Ther 2008; 25: 8: 752-774.

The authors declare that there are no conflicts of interest present.